{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:13:26Z","timestamp":1792592006078,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":384,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014931","name":"Arrowhead Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014931","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jacc.2025.03.496","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T08:10:03Z","timestamp":1742199003000},"page":"1839-1854","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and\u00a0Number\u00a0in\u00a0Hypertriglyceridemia"],"prefix":"10.1016","volume":"85","author":[{"given":"Christie M.","family":"Ballantyne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5599-0633","authenticated-orcid":false,"given":"Robert S.","family":"Rosenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Melquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hellawell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Leeper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2025.03.496_bib1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2337\/diabetes.52.2.453","article-title":"Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance","volume":"52","author":"Garvey","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.jacc.2025.03.496_bib2","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.jacc.2015.03.544","article-title":"Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins","volume":"65","author":"Schwartz","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.03.496_bib3","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.03.496_bib4","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.03.496_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.03.496_bib6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1373\/clinchem.2017.279463","article-title":"Remnant cholesterol and myocardial infarction in normal weight, overweight, and obese individuals from the Copenhagen General Population Study","volume":"64","author":"Varbo","year":"2018","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2025.03.496_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11883-024-01258-8","article-title":"The emerging potential of apolipoprotein C-III inhibition for ASCVD prevention: A State-of-the-Art Review","volume":"27","author":"Maidman","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacc.2025.03.496_bib8","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1161\/CIRCGENETICS.113.000369","article-title":"Rare variant APOC3 R19X is associated with cardio-protective profiles in a diverse population-based survey as part of the Epidemiologic Architecture for Genes Linked to Environment Study","volume":"7","author":"Crawford","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacc.2025.03.496_bib9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.03.496_bib10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.03.496_bib11","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A\u00a0null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.jacc.2025.03.496_bib12","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.03.496_bib13","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.03.496_bib14","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jacl.2018.08.010","article-title":"Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: the EPIC-Norfolk prospective population study","volume":"12","author":"van Capelleveen","year":"2018","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.03.496_bib15","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.03.496_bib16","first-page":"746","article-title":"Development and population results of a fully automated homogeneous assay for LDL triglyceride","volume":"2","author":"Ito","year":"2018","journal-title":"J\u00a0Appl Lab Med"},{"key":"10.1016\/j.jacc.2025.03.496_bib17","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.3390\/nu15112638","article-title":"Characterisation of fasting and postprandial NMR metabolites: insights from the ZOE PREDICT 1 study","volume":"15","author":"Bermingham","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.jacc.2025.03.496_bib18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jacc.2022.10.019","article-title":"Elevated LDL Triglycerides and atherosclerotic risk","volume":"81","author":"Balling","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.03.496_bib19","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jacl.2007.10.001","article-title":"LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study: implications for LDL management","volume":"1","author":"Cromwell","year":"2007","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.03.496_bib20","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1093\/ajcp\/aqae129.394","article-title":"NMR insights into lipoprotein particles: analyzing correlations with traditional lipid measurements","volume":"162","author":"Adegoke","year":"2024","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jacc.2025.03.496_bib21","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.jacc.2020.02.059","article-title":"Triglyceride-rich lipoprotein cholesterol, small dense LDL cholesterol, and incident cardiovascular disease","volume":"75","author":"Duran","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.03.496_bib22","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/ATVBAHA.114.303284","article-title":"Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study","volume":"34","author":"Hoogeveen","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2025.03.496_bib23","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2337\/db09-1114","article-title":"Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women","volume":"59","author":"Mora","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.jacc.2025.03.496_bib24","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1161\/CIRCULATIONAHA.108.816181","article-title":"Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women","volume":"119","author":"Mora","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.03.496_bib25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.atherosclerosis.2006.05.007","article-title":"LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"192","author":"Mora","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.03.496_bib26","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/CIRCULATIONAHA.111.073684","article-title":"Lipids and lipoproteins and risk of different vascular events in the MRC\/BHF Heart Protection Study","volume":"125","author":"Parish","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.03.496_bib27","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","article-title":"Apolipoprotein B particles and cardiovascular disease: a narrative review","volume":"4","author":"Sniderman","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.03.496_bib28","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.03.496_bib29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.03.496_bib30","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2337\/diacare.24.2.350","article-title":"Differential influence of LDL cholesterol and triglycerides on lipoprotein(a) concentrations in diabetic patients","volume":"24","author":"Hernandez","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.03.496_bib31","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.03.496_bib32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0021-9150(93)90117-D","article-title":"Plasma triglycerides and lipoprotein(a): inverse relationship in a hyperlipidemic Italian population","volume":"101","author":"Werba","year":"1993","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.03.496_bib33","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jacl.2022.06.005","article-title":"Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia","volume":"16","author":"Karwatowska-Prokopczuk","year":"2022","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.03.496_bib34","article-title":"Association of high-density lipoprotein particles and high-density lipoprotein apolipoprotein C-III content with cardiovascular disease risk according to kidney function: the multi-ethnic study of atherosclerosis","volume":"8","author":"Lamprea-Montealegre","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.03.496_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114212","article-title":"HDL size is more accurate than HDL cholesterol to predict carotid subclinical atherosclerosis in individuals classified as low cardiovascular risk","volume":"9","author":"Parra","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2025.03.496_bib36","first-page":"165","article-title":"The benefits of measuring the size and number of lipoprotein particles for cardiovascular risk prediction: a systematic review and meta-analysis","volume":"35","author":"Quesada","year":"2023","journal-title":"Clin Investig Arterioscler"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725058929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725058929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T01:58:17Z","timestamp":1779242297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725058929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":36,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0735109725058929"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.03.496","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and\u00a0Number\u00a0in\u00a0Hypertriglyceridemia","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.03.496","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}